CareDx to Host Symposium Covering Innovation in Multimodal Surveillance Including AiCAV for Post-Cardiac Transplant Care
BRISBANE, Calif.–(BUSINESS WIRE)– CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will host a symposium to describe the latest innovations in post-cardiac transplant care at the HFSA (Heart Failure Society of America) Annual Scientific Meeting 2022 taking place in Washington, D.C., September 30 – October 3.
“We look forward to HFSA where we will share more on our AI Heart Platform with AiCAV™, a new offering in development that will help to inform clinicians in their assessment of cardiac allograft vasculopathy risk,” said Reg Seeto, CEO and President of CareDx. “For over two decades, CareDx has been leading innovation to improve outcomes for transplant patients and we are extremely proud to extend this leadership with AiKidney™ and AiCAV.” Read the full press release on CareDx.com.